“…Here again, the limitations of Rb KO models are worth highlighting. For instance, Tamoxifen is used to induce Cre recombinase activation in Rb iKO systems ( Naser et al, 2016 ; Vandenbosch et al, 2016 ; Andrusiak et al, 2012 ; Omais et al, 2019 , 2022 ). However, out of 1760 candidate compounds, Tamoxifen was the only drug identified with sufficient affinity to Cdk5 as to disrupt its interaction with p25 and inhibit downstream tau phosphorylation – a defining signature of AD pathophysiology ( Corbel et al, 2015 ).…”